SCHEMBL3011014

SCHEMBL3011014

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(Cc4cc(F)cc(Cl)c4)cs3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 3/20 0.48
RECQL P46063 2/20 0.48
LMNA P02545 2/20 0.47
TSHR P16473 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 2/20 0.47
HTT P42858 1/20 0.47
KDM4E B2RXH2 2/20 0.46
CCR3 P51677 2/20 0.46
HSD17B10 Q99714 2/20 0.45
CCR5 P51681 1/20 0.44
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648489 0.95 ALDH1A1 (0.43) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL2998656 0.94 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3013251 0.94 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3008292 0.93 MAPT (0.45) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3017659 0.93 MAPT (0.55) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3017759 0.91 MAPT (0.47) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3021709 0.90 MAPT (0.57) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3015495 0.89 ALDH1A1 (0.48) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3018100 0.89 ALDH1A1 (0.52) ALDH1A1KMT2AMAPTRECQLLMNA
SCHEMBL3654780 0.89 MAPT (0.41) ALDH1A1KMT2AMAPTRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KMT2A 2680/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.